Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30895155 | 0.87 | BRD9 (0.37) | TYK2 | |
| SCHEMBL27199606 | 0.84 | TYK2 (0.35) | TYK2ALDH1A1LMNAKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL27199658 | 0.79 | TYK2 (0.30) | TYK2 | |
| SCHEMBL16794654 | 0.78 | TYK2 (0.48) | TYK2ALDH1A1LMNABAZ2BRIPK1 | |
| SCHEMBL27199393 | 0.77 | KDM4E (0.36) | LMNAKDM4EGAARAB9AKMT2A | |
| SCHEMBL27199595 | 0.76 | MET (0.35) | TYK2 | |
| SCHEMBL27199331 | 0.72 | CCNT1 (0.32) | ALDH1A1LMNAGAACMA1 | |
| SCHEMBL27199516 | 0.72 | KDM4E (0.35) | KDM4E | |
| SCHEMBL27199323 | 0.70 | ALDH1A1 (0.34) | ALDH1A1KDM4EGAAKMT2A | |
| SCHEMBL30895087 | 0.70 | BRD9 (0.35) | TYK2ALDH1A1LMNAKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885ALDH1A1 4805/4885LMNA 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.